Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 13/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 8/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.61 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.61 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.61 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.61 |
| ▸ | PI4KA | P42356 | 1/20 | 0.61 |
| ▸ | PRKDC | P78527 | 1/20 | 0.61 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13525268 | 0.91 | PIK3CD (0.55) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL14385799 | 0.91 | PIK3CD (0.55) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL3161770 | 0.90 | PIK3CD (0.60) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL3170841 | 0.85 | PIK3CD (0.70) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL3170480 | 0.85 | PIK3CG (0.61) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL3170483 | 0.85 | PIK3CG (0.61) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL3174782 | 0.84 | PIK3CD (0.54) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL14385601 | 0.83 | PIK3CD (0.63) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL14851723 | 0.81 | PIK3CD (0.72) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB | |
| SCHEMBL3177212 | 0.81 | PIK3CD (0.52) | PIK3CDPIK3CGPI4KBPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010057-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010057-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010057-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-14 | — | — | US | disclosed |
| WO-2007129048-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010057-A1 | THIAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASE | NR4A3, NR2E1, NR2E3 | PIK3CD 1423/4885PIK3CG 1541/4885PI4KB 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.